NCT03499041View on ClinicalTrials.gov

A Study of LY3314814 in Participants With Liver Impairment

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 30, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Hepatic Impairment

Interventions

DRUG

LY3314814

Administered orally

Trial Locations (4)

32809

Orlando Clinical Research Ctr, Orlando

33014

Clinical Pharmacology of Miami, Miami

37920

New Orleans Cntr for Clin Res, Knoxville

92780

Orange County Research Center, Tustin

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY